Refine by
Metastatic Prostate Cancer Equipment & Supplies
17 equipment items found
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
LOCAMETZ, after radiolabeling with gallium-68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy, with suspected recurrence based on elevated serum ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease including bone metastases with greater precision and resolution ...
Manufactured by:Olympia Diagnostics, Inc. based inSunnyvale, CALIFORNIA (USA)
A prognostic test kit quantitatively measures the expression levels of a panel of metastasis-specific biomarkers in patient urine sample or biopsy tissue sample to detect existing metastatic prostate cancer and predict prostate cancer that will become metastatic in the ...
by:Pars Isotope Co based inTehran, IRAN
Lu-177-PSMA is a theranostic radiopharmaceutical designed for the treatment of metastatic prostate cancer. Employing the Peptide Receptor Radionuclide Therapy (PRRT) technique, it selectively targets and binds to prostate tumor cells, facilitating the destruction of malignant cells. This unique action stems from its ...
Manufactured by:Cancer Targeted Technology based inWoodinville, WASHINGTON (USA)
CTT’s lead therapeutic product, CTT1403, is a PSMA-targeted 177Lu-labeled agent for prostate cancer that can has superior binding characteristics, long circulation half-life, enhanced tumor uptake and unparalleled anti-tumor efficacy. CTT1403 will specifically deliver the radionuclide, 177Lu, minimizing toxic side effects and more effectively treating ...
by:Pars Isotope Co based inTehran, IRAN
The PARS-LUTOPSMA kit is an innovative theranostic radiopharmaceutical developed by Parsisotope Company, designed specifically for the treatment of metastatic prostate cancer. This kit is notable for being the first of its kind globally, and is used in conjunction with the Lu-177 radioisotope. It targets prostate-specific ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Thymosin β15 is a small actin-binding protein upregulated in highly metastatic rat prostate cancer cells, relative to low metastatic cells.http://www.creative-peptides.com/product/thymosin-item-10-101-100-109.html ...
Manufactured by:LAVA Therapeutics N.V. based inUtrecht, NETHERLANDS
LAVA-1207, a gamma-delta bsTCE targeting the prostate specific membrane antigen (PSMA), has also demonstrated preclinical proof-of-concept. We expect to initiate a Phase I/IIa trial in metastatic castration-resistant prostate cancer in the second half of ...
Manufactured by:Isotopia Molecular Imaging based inPetah Tikva, ISRAEL
Lutetium-177 (Lu-177) is being widely used as a promising radionuclide for targeted therapy and is emerging as a game-changing theranostic isotope for the treatment of neuroendocrine tumors, metastatic castration-resistant prostate cancer (mCRPC) along with its development for new carrier molecules that can provide selective targeting for tumor ...
Manufactured by:BioXcel Therapeutics, Inc. based inNew Haven, CONNECTICUT (USA)
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to induction of IL-18 and IL-1ß, bridging innate & adaptive immunity. BXCL701 is currently being developed for the treatment of aggressive forms of prostate cancer and ...
Manufactured by:Radium Incorporated based inWaynesboro, VIRGINIA (USA)
ClearView Vial Shield can be used for Ac-225 PSMA, I-123 and I-131 mIBG therapies, Lutathera (Lu-177) therapies for Neuroendocrine Tumor Treatment, FDA approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan or 177Lu-PSMA-617) for the treatment of prostate-specific membrane antigen–positive metastatic castration-resistant prostate ...
Manufactured by:Radium Incorporated based inWaynesboro, VIRGINIA (USA)
The ClearView Rolling Shield is a mobile rolling shield available in lead equivalency up to 1’’ Pb.Eq. and is being used in several Theranostics suites and radiotherapies such as Ac-225 PSMA, I-123 and I-131 mIBG therapies, Lutathera (Lu-177) therapies for Neuroendocrine Tumor Treatment, FDA approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan or 177Lu-PSMA-617) for the ...
Manufactured by:Radium Incorporated based inWaynesboro, VIRGINIA (USA)
The ClearView Infusion Pump Shield works for infusion treatments from Ac-225 PSMA, I-123 and I-131 mIBG therapies, Lutathera (Lu-177) therapies for Neuroendocrine Tumor Treatment, FDA approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan or 177Lu-PSMA-617) for the treatment of prostate-specific membrane antigen–positive metastatic castration-resistant ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Docetaxel micellar is a product candidate in early clinical development and is a novel formulation that combines XR-17 with docetaxel - a well-established cytotoxin, currently administered intravenously and containing ethanol. In June 2020, Vivesto partnered with the Swiss Group for Clinical Cancer Research (SAKK) with the aim of conducting the first clinical study on the ...
Manufactured by:Radium Incorporated based inWaynesboro, VIRGINIA (USA)
Designed to place a foley bag connected to a catheter attached to patients undergoing radiotherapy and scans using radiopharmaceuticals over performed by nuclear medicine specialists or radiologists. The see-through container reduces exposure to hospital staff as the see-through feature of ClearView allows to monitor the level of the foley bags without needing to manually handle radioactive ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
Prostate cancer is the most prevalent cancer among men, and it is the second leading cause of cancer death among men in the United States. More than 500,000 cases are diagnosed annually. In the U.S. this year, 1 in 6 males will develop the disease and 30,000 others will die of it. Although prostate ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Castanospermine is an α/ β-glucosidase inhibitor. Castanospermine has anti-inflammatory, antiviral replication and anti-metastatic effects on prostate cancer. Castanospermine can be used as an immunosuppressant to prevent transplant ...